复方地黄汤联合美多巴治疗帕金森病的临床疗效观察
|
摘要
目的:观察中药复方地黄汤联合美多巴治疗帕金森病(PD)的临床疗效。方法:采用随机对照的方法,将50例患者随机分为2组:对照组(25例)使用西药常规药物美多巴治疗,治疗组(25例)使用复方地黄汤结合美多巴治疗,两组疗程均为3个月;观察两组临床疗效及治疗后帕金森病统一评分量表(UPDRS)评分,包括:第一部分(精神、行为和情志)、第二部分(日常活动)、第三部分(运动功能)、第四部分(治疗的并发症)、第五部分(其他症状),及改良的Hoehn-Yahr(H-Y)分级。结果:治疗组、对照组总有效率分别为60.00%、24.00%;组间比较,差异有统计学意义(P<0.01)。治疗8周后,治疗组可明显改善患者的运动症状,UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ和UPDRSⅤ与治疗前比较,均有统计学意义(P<0.05),两组均未见明显不良反应。结论:复方地黄汤联合美多巴治疗PD能很好地改善PD症状,降低不良反应发生率且安全有效,对美多巴具有明显的增效减毒作用。
Objective: To observe the clinical efficacy of Compound Dihuang Decoction combined with Levodopa in the treatment of Parkinson's disease(PD). Methods: Using randomized controlled methods, 50 patients were randomly divided into treatment group(25 cases) and control group(25 cases). The control group received Levodopa treatment, the treatment group was treated with Compound Dihuang Decoction combined with Levodopa, and course of treatment was 3 months for two groups. Clinical curative effect and unified PD rating scale(UPDRS) after treatment were observed, which including five parts, the first part(spirit, behavior, and emotion), the second part(daily activities), the third part(movement function), the fourth part(complications of treatment), and the fifth part(symptoms) score, modified Hoehn-Yahr(H-Y) grading. Results: Total effective rate of the treatment group and the control group were 60.00% and 24.00%, respectively, the difference was statistically significant(P<0.01). After 8 weeks treatment, the symptoms of the patient's movements had been obviously improved in the treatment group, UPDRSⅠ, UPDRSⅡ, UPDRSⅢ,UPDRS Ⅳ and UPDRS Ⅴ compared with before treatment were statistically significant(P<0.05), and no obvious side effects were found in two groups. Conclusion: Compound Dihuang Decoction combined with Levodopa in the treatment of PD can improve the symptoms, reduce adverse action rate, and have significant synergistic effect on Levodopa.
Objective: To observe the clinical efficacy of Compound Dihuang Decoction combined with Levodopa in the treatment of Parkinson's disease(PD). Methods: Using randomized controlled methods, 50 patients were randomly divided into treatment group(25 cases) and control group(25 cases). The control group received Levodopa treatment, the treatment group was treated with Compound Dihuang Decoction combined with Levodopa, and course of treatment was 3 months for two groups. Clinical curative effect and unified PD rating scale(UPDRS) after treatment were observed, which including five parts, the first part(spirit, behavior, and emotion), the second part(daily activities), the third part(movement function), the fourth part(complications of treatment), and the fifth part(symptoms) score, modified Hoehn-Yahr(H-Y) grading. Results: Total effective rate of the treatment group and the control group were 60.00% and 24.00%, respectively, the difference was statistically significant(P<0.01). After 8 weeks treatment, the symptoms of the patient's movements had been obviously improved in the treatment group, UPDRSⅠ, UPDRSⅡ, UPDRSⅢ,UPDRS Ⅳ and UPDRS Ⅴ compared with before treatment were statistically significant(P<0.05), and no obvious side effects were found in two groups. Conclusion: Compound Dihuang Decoction combined with Levodopa in the treatment of PD can improve the symptoms, reduce adverse action rate, and have significant synergistic effect on Levodopa.
引文
[1]P Ylikotila,T Tiirikka,J S Moilanen.Epidemiology of early-onset Parkinson’s disease in Finland.Parkinsonism&Related Disorders,2015,21(8):938-942
[2]陈生弟,乐卫东,陈先文,等.帕金森病.北京:人民卫生出版社,2006:446
[3]The Chinese Medical Association Neurological Branch Movement Disorders and Parkinson’s Disease Group.Diagnosis of Parkinson’s disease.Chinese Journal of Neurology,2006,39(6):408-409
[4]全国锥体外系疾病讨论会.帕金森病及帕金森综合征的诊断标准和鉴别诊断.中华神经精神科杂志,1986,19(5):256
[5]中华中医学会老年脑分会.中医老年颤证诊断和疗效评定标准.北京中医学院学报,1992,15(4):39-40
[6]Prunier C,Tranquart F,Cottier J P,et al.Quantitative analysis of stnatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyrami daldiseases.Nucl Med Commun,2001,22:1207-1214
[7]Fahn S,Elton R L,Members of the UPDRS Development Committee.Unified Parkinson’s disease rating scale Fahn S,Marsden C D,Calne D B,et al.Recent Developments in Parkinsons Disease.Florham Park,NJ:Mac Millan Health Care Information,1987:153-163
[8]何建成.帕金森病中医药治疗的再思考——兼谈“滋肾平肝,化痰活血,解毒散结”是帕金森病的基本治疗法则.中医药通报,2005,4(1):12
[2]陈生弟,乐卫东,陈先文,等.帕金森病.北京:人民卫生出版社,2006:446
[3]The Chinese Medical Association Neurological Branch Movement Disorders and Parkinson’s Disease Group.Diagnosis of Parkinson’s disease.Chinese Journal of Neurology,2006,39(6):408-409
[4]全国锥体外系疾病讨论会.帕金森病及帕金森综合征的诊断标准和鉴别诊断.中华神经精神科杂志,1986,19(5):256
[5]中华中医学会老年脑分会.中医老年颤证诊断和疗效评定标准.北京中医学院学报,1992,15(4):39-40
[6]Prunier C,Tranquart F,Cottier J P,et al.Quantitative analysis of stnatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyrami daldiseases.Nucl Med Commun,2001,22:1207-1214
[7]Fahn S,Elton R L,Members of the UPDRS Development Committee.Unified Parkinson’s disease rating scale Fahn S,Marsden C D,Calne D B,et al.Recent Developments in Parkinsons Disease.Florham Park,NJ:Mac Millan Health Care Information,1987:153-163
[8]何建成.帕金森病中医药治疗的再思考——兼谈“滋肾平肝,化痰活血,解毒散结”是帕金森病的基本治疗法则.中医药通报,2005,4(1):12